Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
SAB Biotherapeutics, Inc.
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
May 4, 2026
SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
May 4, 2026
SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
May 3, 2026
SAB BIO Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
May 3, 2026
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
May 2, 2026
SAB BIO to Participate in Upcoming Investor Conferences
April 30, 2026
←
Previous Page
1
2